Table 2.
Unadjusted and adjusted odd ratios for clinical remission at M6 and last follow-up of baseline indicators (M0)
| Unadjusted | Adjusted | |||||||
|---|---|---|---|---|---|---|---|---|
| Effect | Odds Ratio | 95% Wald Confidence Limits | Type 3 Analysis P Value | Odds Ratio | 95% Wald Confidence Limits | Type 3 Analysis P Value | ||
| M6 | ||||||||
| Age, yr | 1.02 | 0.98 | 1.07 | 0.38 | 1.02 | 0.97 | 1.07 | 0.37 |
| Sex | 0.93 | 0.96 | ||||||
| Men | 1 | 1 | ||||||
| Women | 0.94 | 0.25 | 3.53 | 1.04 | 0.24 | 4.54 | ||
| PLA2R1-Ab at M0, RU/ml | 1.00 | 0.99 | 1.00 | 0.67 | 1.00 | 0.99 | 1.00 | 0.44 |
| Treatment | 0.37 | 0.21 | ||||||
| NIAT | 1 | 1 | ||||||
| NIAT and RITUX | 1.73 | 0.52 | 5.69 | 2.37 | 0.62 | 9.06 | ||
| Spreading M0 | 0.02 | 0.02 | ||||||
| No | 1 | 1 | ||||||
| Yes | 0.23 | 0.07 | 0.79 | 0.16 | 0.04 | 0.72 | ||
| Last follow-up | ||||||||
| Age, yr | 1.01 | 0.98 | 1.05 | 0.51 | 1.02 | 0.98 | 1.07 | 0.38 |
| Sex | ||||||||
| Men | 1 | 0.92 | 1 | 0.54 | ||||
| Women | 1.06 | 0.33 | 3.39 | 1.54 | 0.4 | 5.99 | ||
| PLA2R1-Ab at M0, RU/ml | 1.00 | 0.99 | 1.00 | 0.22 | 1.00 | 0.99 | 1.00 | 0.86 |
| Treatment | ||||||||
| NIAT | 1 | 0.12 | 1 | 0.04 | ||||
| NIAT and RITUX | 2.34 | 0.81 | 6.74 | 3.72 | 1.05 | 13.2 | ||
| Spreading M0 | ||||||||
| No | 1 | 0.01 | 1 | 0.01 | ||||
| Yes | 0.18 | 0.05 | 0.65 | 0.15 | 0.03 | 0.64 | ||
Note that spreading at baseline is the only predictor of remission at M6, and it also predicts remission at last follow-up before any treatment modification, independently from PLA2R1-Ab titer.